Ms Carol P Ibach, CNS, RXN, APRN in Montrose, CO - Clinical Nurse Specialist

Ms Carol P Ibach, CNS, RXN, APRN is a Clinical Nurse Specialist - Psychiatric/mental Health, Community based in Montrose, Colorado. Ms Carol P Ibach is licensed to practice in Colorado (license number 46632) and her current practice location is 605 E Miami Rd, Montrose, Colorado. She can be reached at her office (for appointments etc.) via phone at (970) 249-9694.

NPI number for Ms Carol P Ibach is 1184659377 and her current mailing address is Po Box 1208, Montrose, Colorado. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1184659377.

Contact Information

	Ms Carol P Ibach, CNS, RXN, APRN
	605 E Miami Rd, Montrose, CO 81401
	(970) 249-9694
	(970) 249-2955

Provider's Profile

Full Name	Ms Carol P Ibach
Gender	Female
Speciality	Clinical Nurse Specialist - Psychiatric/mental Health, Community
Location	605 E Miami Rd, Montrose, Colorado
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1184659377
Provider Enumeration Date: 07/12/2006
Last Update Date: 08/28/2012

Medical Identifiers

Medical identifiers for Ms Carol P Ibach such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1184659377	NPI	-	NPPES
84-0561224	Other	CO	TAX ID

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
364SP0812X	Clinical Nurse Specialist - Psychiatric/mental Health, Community	46632 (Colorado)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ms Carol P Ibach is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ms Carol P Ibach, CNS, RXN, APRN Po Box 1208, Montrose, CO 81402-1208 Ph: (970) 252-3200	Ms Carol P Ibach, CNS, RXN, APRN 605 E Miami Rd, Montrose, CO 81401 Ph: (970) 249-9694

News Archive

European study endorses dashboards for public reporting during the COVID-19 pandemic

Researchers explore the development of COVID-19 dashboards during the first year of the pandemic.

Researcher finds no long-term benefit of using glucosamine for knee joint pain

A popular food supplement used to treat osteoarthritis pain in knee joints has been shown to have no long-term beneficial effect, according to a national study conducted by a University of British Columbia post-doctoral fellow working at the Arthritis Research Centre of Canada

New study suggests that 21-day quarantine period not enough to completely prevent Ebola

As medical personnel and public health officials are responding to the first reported cases of Ebola Virus in the United States, many of the safety and treatment procedures for treating the virus and preventing its spread are being reexamined. One of the tenets for minimizing the risk of spreading the disease has been a 21-day quarantine period for individuals who might have been exposed to the virus. But a new study by Charles Haas, PhD, a professor in Drexel's College of Engineering, suggests that 21 days might not be enough to completely prevent spread of the virus.

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

StemCells, Inc. announced today that it welcomes the approval yesterday by the National Institutes of Health (NIH) of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009.

Ms Carol P Ibach, CNS, RXN, APRN - Clinical Nurse Specialist in Montrose, CO